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New specific European eel (Anguilla anguilla) recombinant gonadotropins (aarGths) 34 
produced in the ovarian cells of Chinese hamsters (CHO) were used to induce maturation 35 
in captive male eels. In the first experiment, five different hormonal treatments were 36 
assayed: one group was given a constant dose of recombinant European eel follicle-37 
stimulating hormone (aarFsh; 4 µg/fish) for 9 weeks, and the second group received a 38 
constant dose of recombinant European eel luteinizing hormone (aarLh; 2 µg/fish) also 39 
for 9 weeks. The other three groups were injected with different combinations of both 40 
aarGths (some doses constant, some variable). All five treatments stimulated androgen 41 
synthesis, but the increase was more pronounced in the fish treated with a combination of 42 
both aarGths. Unlike aarLh, aarFsh alone was able to induce spermiation, the best results 43 
were achieved in the fish that were treated with a constant dose of aarFSH and an 44 
increasing dose of aarLH, with spermiation being induced (20% motile cells) despite the 45 
fact that these fish were immature at the start of the experiment. In order to improve sperm 46 
quality, a second experiment was performed. Immature males received three constant 47 
doses of aarFsh (2.8, 1.4 or 0.7 µg/fish) and increasing doses of aarLh (every 3 weeks; 1, 48 
2, 6 µg/fish). All the treatments induced spermiation, however the best sperm quality 49 
(with ≥50% motile cells) was observed in the males treated with the highest dose of 50 
aarFsh. In conclusion, these specific recombinant gonadotropins have demonstrated their 51 
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1. Introduction 58 
The European eel (Anguilla anguilla) population has decreased by 95-99%, compared to 59 
levels in 1960-80 [1], and as a result the species has been placed on the Red List of 60 
Threatened Species and listed as “Critically Endangered” by the International Union for 61 
Conservation of Nature (IUCN). However, the wild eel populations still sustain important 62 
fisheries and aquaculture industries (based on harvesting juvenile ‘glass eels’ from the 63 
wild) in Europe. To reduce the dependency of eel industry on wild populations, and even 64 
for stocking purposes, the development of new protocols to reproduce this species in 65 
captivity is crucial. The full life-cycle of the European eel has yet to be successfully 66 
closed in captivity, thus limiting aquaculture to ranching of wild caught glass eel. Some 67 
of the main hurdles encountered include the stagnation of puberty [2], finding alternative 68 
treatments to induce full maturation [3,4] and obtaining high quality gametes [5].  69 
Gonadal activity (steroidogenesis and gametogenesis) is controlled by pituitary 70 
gonadotropin hormones (Gths), responsible for the control of reproduction in both teleost 71 
fish and other vertebrates. The follicle-stimulating hormone (Fsh) regulates the Sertoli 72 
cell activities, including structural, nutritional and regulatory (paracrine) support of germ 73 
cell development, and the luteinizing hormone (Lh) regulates the Leydig cell sex steroid 74 
production [6]. Both Gths, Lh and Fsh, are considered the most important pituitary 75 
hormones regulating testicular physiology.  76 
At present, it is possible to induce eel maturation using exogenous hormones in both 77 
males [3,7], and females [8], but these hormonal treatments result in low rates of 78 
fertilization and hatching, mainly attributed to low gamete quality [9]. The traditional 79 
method used to induce eel maturation has involved the use of human chorionic 80 
gonadotropin (hCG) in males [10] and carp or salmon pituitary extract in females [11]. 81 
However, the administration of non-native Lh or equivalents has not resulted in a reliable 82 
level of percentage of matured fish nor gamete quality [12,13]. Therefore, in order to 83 
solve the reproductive problems encountered when using the current hormonal treatments 84 
in both male and female eels, a native eel Fsh purified from immature Japanese eel 85 
(Anguilla japonica) was tested to induce spermatogenesis in vitro [14]. The native Fsh 86 
was able to stimulate androgen synthesis but, due to the difficulty in obtaining an adequate 87 
amount of native Gths, tools for producing recombinant gonadotropins (rGths) in eel were 88 
developed [15]. 89 
Later on, a recombinant Japanese eel Fsh (ajrFsh) was synthesized using methylotropic 90 
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yeast (Pichia pastoris), and was successful in inducing steroidogenesis in the gonads of 91 
both sexes cultured in vitro [14,16,17]. In vivo trials were also carried out on male eels, 92 
inducing testicular growth and the beginning of spermatogenesis [18]. Subsequently, with 93 
the aim of improving the biological activity of rGths, new Japanese eel rGths were 94 
produced using a Drosophila expression system [19]. Both recombinant Fsh and Lh 95 
induced complete spermatogenesis in in vitro conditions, but small effects were observed 96 
in vivo. In order to obtain a large-scale production of rGths, Hayakawa et al. [20] used a 97 
baculovirus-silkworm larvae system to produce rGths in Japanese eel. Complete 98 
spermatogenesis was accomplished in vivo, but no male reached spermiation [20–22].  99 
rGths have also been tested in other teleosts [15]. They have been successful in inducing 100 
steroidogenesis and gonad development both in vitro and in vivo, however, the in vivo 101 
results have been variable [23]. rGths have been reported to induce androgenesis e.g. in 102 
zebrafish (Danio rerio; [24]) and Russian sturgeon (Acipenser gueldenstaedtii; [25]) and 103 
recombinant Fsh has triggered spermatogenesis in immature European sea bass 104 
(Dicentrarchus labrax; [26]). In general, the hormonal treatment was unable to induce 105 
spermiation in vivo, except in the case of goldfish (Carassius auratus; [27]) and European 106 
sea bass [28], but both these cases the treated fish were already sexually mature at the 107 
beginning of the experiment. A different approach to the administration of rGths was to 108 
inject a plasmid containing the Gth sequence directly into the muscle. Mazón et al. [28] 109 
reported an improvement in sperm quality of European sea bass using an Lh sequence, 110 
but again the treated fish were already sexually mature at the beginning of the 111 
experiments. 112 
The main objective of this study was to test if new European eel recombinant 113 
gonadotropins (aarFsh and aarLh) were able to induce in vivo eel spermatogenesis and 114 
spermiation in captivity, and demonstrate the differential function of fsh and lh during 115 
spermatogenesis in eel.  116 
 117 
2. Materials and methods 118 
2.1 Fish maintenance 119 
Immature yellow European eel males from the Valenciana de Acuicultura, S.A fish farm. 120 
(Puzol, Valencia; East coast of Spain) were moved to the aquaculture facilities at the 121 
Universitat Politècnica de València (UPV, Spain). The fish (6-8 fish/aquarium) were 122 
distributed into 150-L aquaria equipped with separate recirculation systems, a 123 
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temperature control system (with heaters and coolers) and completely covered to maintain 124 
as maximum possible a constant dark photoperiod. Before the hormonal treatment, the 125 
eels were gradually acclimatized from freshwater to sea water (37 g/L) increasing the 126 
salinity 10‰ each 2 days for 8 days, and 2 days more of resting at 37‰. The temperature, 127 
oxygen level and pH of rearing were 20 ºC, 7-8 mg/L (thanks to aerators) and ~8.2, 128 
respectively. Finally, due to its ethology during its reproductive migration, the fish were 129 
fasted throughout the treatment.  130 
 131 
2.2 Production of recombinant gonadotropins 132 
Homologous single-chain recombinant Fsh and Lh, containing a modified linker, were 133 
produced in the ovarian cells of Chinese hamster (CHO) in suspension by Rara Avis 134 
Biotec S.L. (Valencia, Spain) using in-house technology. The purity was determined by 135 
western blot using specific antibodies and the final amount of rGth was quantified by 136 
immunoassay using these same specific antibodies.  137 
European eel β and α subunits (GenBank accession numbers: CAA43373.1 (α common 138 
subunit), AAN73407.1 (βfsh), CAA43374.1 (βlh) were used to obtain the single chain 139 
Gths. 140 
 141 
2.3 Experimental setup: hormonal treatments and samplings 142 
Two experiments were carried out in order to evaluate the effect of specific rGths had on 143 
inducing maturation in European eels in captivity. In experiment 1 (October to December; 144 
2015), the aim was to test the effect of aarFsh and aarLh on their own, as well as the 145 
optimum combination of both rGths. Meanwhile in experiment 2 (January to March; 146 
2016), the objective was to improve maturation and sperm quality using the treatment that 147 
yielded the best results in terms of aquaculture purposes in experiment 1.  148 
Experiment 1 149 
Sixty immature male eels were used in this trial (mean body weight = 89.21±5.44 g; mean 150 
body length = 38.12±2.28 cm). Before starting the hormonal treatments, 10 eels were 151 
sampled as soon as they arrived at our facilities (thus in freshwater, FW); and 10 new eels 152 
were sacrificed after they had been acclimatized to sea water (SW). Subsequently, 153 
intramuscular hormonal treatments were administered weekly using the protocol 154 
described by Asturiano et al. [10]. The fish were anaesthetized with benzocaine (60 ppm) 155 
before receiving the hormone by intramuscular injection. 156 
Forty immature fish (90.04±1.92 g; 38.10±0.33 cm) underwent five hormonal treatments 157 
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(~8 males per treatment; Fig. 1) for 9 or 11 weeks. Two groups, group F and L, were 158 
injected once per week for 9 weeks only with aarFsh (4 µg/fish; Fig. 1A) or aarLh (2 159 
µg/fish; Fig. 1B) respectively. The other three groups, F/L, F/LI and FD/LI, were injected 160 
with different combinations of both hormones once per week for 11 weeks. Group F/L 161 
(Fig. 1C) was treated with 4 µg aarFsh/fish for the first 4 weeks, followed by 2 µg 162 
aarLh/fish for the last 8 weeks. Group F/LI (Fig. 1D) was treated with 4 µg aarFsh/fish 163 
throughout the experimental period, combined with increasing doses of aarLh, from 0.5 164 
to 2 µg/fish (between weeks 1 and 4) and then a constant dose of 2 µg aarLh/fish from 165 
week 4. Group FD/LI (Fig. 1E) received decreasing doses of aarFsh from 4 to 0.5 µg/fish 166 
(from week 3 to week 8) combined with increasing doses of aarLh from 0.5 to 2 µg/fish 167 
(between week 1 and week 4) and then a constant dose of 2 µg aarLh/fish from the 4th 168 
week on. 169 
In order to evaluate the progression of maturation, every two weeks blood samples were 170 
taken for steroids analyses, and biometric parameters, such as eye index (EI = 100 p 0.25 171 
(Dh + Dv)2/Lt); Lt: total length; Dh: horizontal distance; Dv: vertical distance; [29]) and 172 
fin colour (FC; 0 = Transparent, 1= Light grey, 2= Dark grey, 4 = Black) were registered. 173 
Both biometric parameters have previously been used in eel as indicators of maturation 174 
[7]. 175 
After beginning of spermiation, samples were collected and analysed as described by 176 
Gallego et al. [30]. Once the experiment had finished, the gonadosomatic index was 177 
calculated (GSI = 100 gonad weight/total body weight) and testis samples were collected 178 
to determine the stage of development by histology. 179 
Experiment 2  180 
In order to improve eel maturation in captivity, new hormonal treatments were designed, 181 
with the treatment that yielded the best results in experiment 1 in terms of aquaculture 182 
requirements, being used as the basis. The aarFsh levels were reduced slightly, in order 183 
to find the minimum effective dose, whereas the aarLh dose was increased to enhance its 184 
effect on the spermatogenesis process.  185 
As with experiment 1, before starting the hormonal treatments, 8 immature eels were 186 
sampled after they had been acclimatized to sea water (SW). Subsequently, 72 immature 187 
fish (99.98±2.01 g; 38.56±2.28 cm) underwent three intramuscular hormonal treatments 188 
(24 males/treatment), administered weekly for a total of 12 weeks. The males received a 189 
constant dose of aarFsh, with the Low treatment group receiving 0.7, and the Medium 190 
and High treatment groups receiving 1.4 and 2.8 µg/fish respectively. This was combined 191 
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with an increasing dose of aarLh: 1, 2, 6 µg/fish. The aarLh dose was increased every 3 192 
weeks, from the 3rd week of the treatment (Fig. 2). In order to evaluate the progression of 193 
maturation, three males per treatment were sacrificed every 3 weeks to collect blood and 194 
gonad samples, and to measure biometric parameters, including GSI.  195 
During the weeks of spermiation, sperm samples were collected and analysed as described 196 
by Gallego et al. [30]. 197 
 198 
2.4 Gonadal histology 199 
For experiment 1, sections from the mid-part of testis were preserved in 4% buffered 200 
(PBS) glutaraldehyde at 4 ºC overnight. The tissue was dehydrated and embedded in 201 
Technovit® 7100. Nevertheless, in the experiment 2, sections from the mid-part of testis 202 
were preserved in 10% formalin buffered at pH 7.4, dehydrated in ethanol and embedded 203 
in paraffin. In both cases, between 10-20 sections/testis (5 µm thickness) were cut with a 204 
Microm HM325, and stained with 1% toluidine blue (Exp. 1) or with a Shandom 205 
Hypercut manual microtome and stained with haematoxylin and eosin (Exp. 2). Two 206 
slides/testis were observed with a Nikon Eclipse E-400 microscope, and pictures were 207 
taken with a Nikon DS-5M camera attached to the microscope. The stages of 208 
spermatogenesis were determined by the following parameters: germ cell types present 209 
in the testis and their relative abundance (according to Leal et al. [31]),  the degree of 210 
development of the seminal tubules and the GSI by the male at the time of sacrifice [32] 211 
(see supplementary Fig.1: SPG1: Dominance of A spermatogonia, with a general absence 212 
of lobule lumen. Gonad in non- proliferating stage. Stage SPG2: Dominance of A 213 
spermatogonia, with some B spermatogonia and presence of lobule lumen. Stage SPC1: 214 
Dominance of B spermatogonia and presence of spermatocytes. Stage SPC2: Dominance 215 
of spermatocytes and B spermatogonia. Stage SD: is characterized by an abundance of 216 
spermatids. Stage SPZ1: Early spermiation stage. Stage SPZ2: Stage of maximum 217 
spermiation, showing fusion of sperm lobules.  218 
 219 
2.5 Plasma steroid assays  220 
Blood was collected and centrifuged at 3500 r.p.m. for 15 min, and the blood plasma was 221 
stored at -80 ºC until steroid analysis.  222 
Plasma levels of testosterone (T) and 11-ketotestosterone were analyzed by a specific 223 
enzyme immunoassay (EIA) following the methods developed for European sea bass 224 
[33,34]. The lower limits of detection (80% binding) were 0.00117 ng/ml for 11-KT and 225 
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0.019 ng/ml for T. Analysis of serial dilutions of eel plasma dilutions were shown to be 226 
parallel to the standard curve. The inter-assay coefficients of variation were 9.74% (n=7) 227 
for 11-KT and 12.6% (n=7) for T. The intra-assay coefficients of variation were 8.64% 228 
(n=10) for 11-KT y 2.93% (n=4) for T.  229 
 230 
2.6 Sperm collection and evaluation 231 
Sperm samples were collected 24 h after the administration of the hormone to obtain the 232 
highest quality sperm [12]. After the eels were anesthetized, the genital area was first 233 
cleaned with distilled water and thoroughly dried to avoid the sperm becoming 234 
contaminated with faeces, urine or sea water. The sperm was then collected by the 235 
application of gentle abdominal pressure, and with the help of a small-modified aquarium 236 
air pump which produced a vacuum the sperm was collected into plastic Falcon tubes. 237 
The sperm was diluted (1:10) before being activated in P1 medium [35]; in mM: 125 238 
NaCl, 20 NaHCO3, 2.5 MgCl2⋅6H2O, 1 CaCl2⋅2H2O, 30 KCl). The sperm was activated 239 
by mixing 0.5 µl of this dilution with 4 µl of artificial sea water and 2% BSA (w/v), and 240 
by adjusting the pH to 8.2 [12]. All the motility analyses were performed in triplicate 241 
using the motility module of ISAS (Proiser R+D, S.L.; Paterna, Spain) as described by 242 
Gallego et al. [30]. 243 
The sperm parameters considered in this study were total motility (TM, %), defined as 244 
the percentage of motile cells; progressive motility (PM, %), defined as the percentage of 245 
spermatozoa which swim in essentially a straight line; curvilinear velocity (VCL, µm/s), 246 
defined as the time-average velocity of a sperm head along its actual curvilinear 247 
trajectory; straight line velocity (VSL, µm/s), defined as the time/average velocity of a 248 
sperm head along the straight line between its first detected position and its last position. 249 
Spermatozoa were considered immotile if their VCL was lower than 10 µm/s.  250 
 251 
2.7 Statistical analysis 252 
The mean and standard errors were calculated for all the biometric indexes (GSI, EI, and 253 
FI) and sperm parameters (volume, density, motility and rest of kinetic parameters). 254 
Shapiro-Wilk and Levene tests were used to check the normality of data distribution and 255 
variance homogeneity, respectively. One-way analyses of variance (ANOVA) and 256 
Student's t-test were used to analyse data (normal distribution) between groups at the 257 
same week. Significant differences between treatments were detected using the Tukey 258 
multiple range test (P<0.05). For non-normally distributed populations, Kruskal-Wallis 259 
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one-way ANOVA on ranks and Mann-Whitney U-test were used. Moreover, GLM for 260 
repeated measures was used for comparing data over the weeks within the same hormonal 261 
treatment; and significant differences were also detected using the Tukey multiple range 262 
test (P<0.05). All statistical analyses were performed using the statistical package SPSS 263 
version 19.0 for Windows software (SPSS Inc., Chicago, IL, USA). 264 
 265 
2.8 Human and Animal Rights 266 
This study was carried out in strict accordance with the recommendations given in the 267 
Guide for the Care and Use of Laboratory Animals of the Spanish Royal Decree 53/2013 268 
regarding the protection of animals used for scientific purposes (BOE 2013). The protocol 269 
was approved by the Experimental Animal Ethics Committee from the Universitat 270 
Politècnica de València (UPV) and final permission was given by the local government 271 
(Generalitat Valenciana, Permit Number: 2014/VSC/PEA/00147). The fish were 272 
sacrificed using anaesthesia and all efforts were made to minimize suffering. The fish 273 
were not fed throughout the experiment and were handled in accordance with the 274 
European Union regulations concerning the protection of experimental animals (Dir 275 
86/609/EEC). 276 
 277 
3. Results 278 
3.1 Experiment 1 279 
Biometric parameters: EI, FC and GSI 280 
Regarding Eye Index (EI; Table 1), significant differences between the FW and SW 281 
values (before hormone administration), were observed in all the groups. Fin Colour (FC) 282 
became progressively dark throughout the hormonal treatment, becoming almost 283 
completely black around the week 5 in groups F, L, F/LI and FD/LI, and around week 7 284 
in group F/L. 285 
Before hormonal treatment, the eels showed a GSI of 0.20±0.05% in FW and 0.22±0.04% 286 
in SW (Fig. 3). No significant differences were found at the end of the different hormonal 287 
treatments except in group F/LI, which showed a mean GSI of 3.83±0.84% after eleven 288 
weeks. On the other hand, eels from groups F and FD/LI showed increases in GSI (of 289 
around 1%) at week 9 and 11, respectively. The difference however was not significant 290 
compared to the initial values (FW and SW). 291 
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Progression of gonad development 292 
Regarding testis development (Figs. 4 and 5), aarFsh alone was able to induce 293 
spermatozoa stages (SPZ1, SPZ2) in 37.5% of fish, and SPD stage in 25% of fish. In 294 
contrast, all aarLh treated males were less developed, with 100% being in stage SPG2, 295 
with a dominance of SPGA, clusters of differentiated SPGA (Fig. 5B), and in some cases 296 
the presence of SPGB. In groups F/LI and FD/LI, the treatments which combined aarFsh 297 
and aarLh, 87.5% of fish reached normal spermiation stages (SPZ1 and SPZ2). However, 298 
treatment F/L, also combining both hormones, induced abnormal testis development in 299 
50% of fish: whilst the testis had the structure of stage SPG2, with dominance of SPGA, 300 
a few small spermatozoa cysts were present. We considered this to be a regressive stage, 301 
with the spermatocytes and even the SPGB having disappeared from the testis after an 302 
initial production of spermatozoa. This is supported by the fact that apoptotic cells were 303 
observed in this stage of development (Fig. 5D). 304 
Steroid evolution during hormonal treatment 305 
The administration of aarFsh or aarLh alone (groups F and L, respectively) was enough 306 
to initiate steroidogenesis (Fig. 6), inducing the production of both 11-KT and T. 307 
However, the treatment which combined both aarGths (groups F/LI and FD/LI) yielded 308 
higher levels of these steroids. On the other hand, a sequential administration of aarGths 309 
(group F/L) provided a steroid profile closer to group F and L than to the profiles showed 310 
by aarGths combined treatments (group F/LI and FD/LI). 311 
Sperm quality analyses 312 
Eels treated with a single Gth showed the lowest percentage of spermiating males (Fig. 313 
7A): in the case of aarLh (group L) non-spermiating males at all were observed, whereas 314 
in group F (aarFsh) they were only registered in weeks 8 and 9. The percentage of 315 
spermiating males was higher when aarFsh and aarLh were combined.  316 
Group F/LI (which received constant doses of aarFsh and increasing doses of aarLh) 317 
yielded the best results, with 100% of males reaching spermiation at weeks 10 and 11. 318 
Sperm volumes were remarkably low in all the treatments, with no significant differences 319 
observed over the course of the weeks neither within the individual groups nor between 320 
the different treatments (Fig. 7B, see also supplementary data: Fig. 2A). The highest 321 
density values were observed in group F/LI, with significant differences observed in 322 
weeks 8 and 10 (Fig. 7C). 323 
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Regarding sperm quality, total (TM) and progressive (PM) motilities (Figs. 8A and 8B) 324 
yielded the highest values at week 8 in group F/LI (without significant differences inter-325 
treatments but with significant differences intra-treatment; see also supplementary data: 326 
Fig. 2B), with the maximum values reached being 20% TM and 2% PM. From the 8th 327 
week on, males from all the treatments displayed a marked decrease in total and 328 
progressive motility.  329 
The kinetic parameters of the sperm cells (VCL and VSL; Figs. 8C and 8D) showed a 330 
similar evolution in groups F/LI and FD/LI, with the highest peak being observed at week 331 
8 followed by a progressive decrease until the end of the treatment. Groups F and F/L did 332 
not show any variations over the course of the weeks and the velocity values remained 333 
low and constant throughout the weeks of spermiation. 334 
 335 
3.2 Experiment 2 336 
Biometric parameters: EI, FC and GSI 337 
Regarding EI (Table 2), a significant increase was observed in all the groups between the 338 
initial SW values and the values recorded in the 3rd week. This was followed by a 339 
continual increase in this parameter throughout the hormonal treatments, with peaks in 340 
weeks 9 and 12. FC progressively darkened, but at different rates depending on the 341 
treatment, becoming almost completely black in weeks 6, 9 and 12 in the High, Medium 342 
and Low treatments, respectively. 343 
Irrespective of the treatment, no significant differences were observed in the GSI until the 344 
12th week, when the values became significantly higher than controls, reaching values of 345 
0.9, 1.8 and 4.3% in the Low, Medium and High treatments, respectively (Fig. 9). In 346 
addition, significantly higher GSI values were achieved in the High treatment compared 347 
to the other treatments, thus indicating an interaction between factors (week and 348 
treatment). 349 
Progression of gonad development 350 
Regarding testis development (Table 3), 6 weeks after the start of the treatments, the High 351 
and Medium groups demonstrated the most advanced development, with 33% of fish 352 
from both groups having arrived at stage SPC2, with meiosis as the dominant process. 353 
The Low treatment did not induce an evident testis development until week 9, when first 354 
spermatogonia B, and well developed testis lumen were observed. In all the treatments, 355 
the spermiating stages (SPZ1 and SPZ2) were reached in week 12, but only high doses of 356 
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aarFsh resulted in 100% of eel males reaching the spermiation stages (SPZ1 and SPZ2), 357 
with the Medium and Low doses only able to induce these stages in 57% (4/7) and 42% 358 
(3/7) of the fish, respectively. 359 
Steroid evolution during hormonal treatment 360 
The administration of aarFsh and aarLh throughout the Low and Medium treatments was 361 
able to initiate the production of 11-KT and T (Fig. 10), but without reaching significant 362 
differences in comparison to the initial levels. However, the aarGths doses used in the 363 
High treatment generated a progressive increase in the plasma levels of both androgens, 364 
which reached their highest values in the 6th week (Fig. 10A), followed by a progressive 365 
decrease until the end of the treatment. 366 
Sperm quality analyses 367 
The percentage of spermiating males was constant (around 60%) at High treatment for 368 
first weeks of spermiation, but then they increased to 80% at week 11 (Fig. 11A). The 369 
Medium and Low treated males did not begin to produce sperm until weeks 9 and 10, 370 
respectively, reaching approximately 40% (Low group) and 70% (Medium group) of 371 
spermiating males in week 12.  372 
Sperm volumes were remarkably low and showed a progressive increase over the weeks 373 
(Fig. 11B; see also supplementary data: Fig. 3A). The High treatment yielded the highest 374 
volumes every week, with the values being significantly higher than those recorded in the 375 
Medium and Low treatments at week 10. Sperm density values followed the same pattern 376 
as volume, but with significantly lower values in the Low treatment at weeks 10, 11 and 377 
12 (Fig. 11C). 378 
Regarding the kinetic parameters, total (TM) and progressive (PM) motility (Figs. 12A 379 
and 12B; see also supplementary data: Fig. 3B), yielded the best values in the High 380 
treatment, with significant differences at weeks 10 and 12, and maximum values of 60 381 
and 30% of TM and PM, respectively. Moreover, by analyzing these parameters an 382 
interaction between factors (week and treatment) became apparent. The motility values 383 
of the sperm in the Medium and Low groups did not reach more than 50% in any week. 384 
The velocity values (VCL and VSL; Figs. 12D and 12E) were significantly higher in the 385 
group treated with the High dose of aarFsh, with the highest peak being observed in week 386 
10 followed by a progressive decrease until the end of the treatment. Little or no variations 387 
were observed in the Medium and Low treatments over the course of the weeks, and the 388 
velocity values remained low and regular during the weeks of spermiation. 389 
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4. Discussion 390 
Experiment 1 391 
The present study demonstrated that the aarGths produced by a CHO system are 392 
biologically active and their half-life is long enough to induce in vivo effects. aarFsh alone 393 
and all the combined aarFsh and aarLh treatments were able to induce spermiation, 394 
whereas aarLh alone failed to induce completion of the maturation cycle, with the fish 395 
maturation being interrupted at the pre-meiotic stage (SPG2), with testis showing only 396 
SPGA and some lumen development.  397 
Biometric parameters: EI, FC and GSI  398 
With the aim of monitoring the progression of maturation, different biometric parameters 399 
(EI and FC) were used. EI changed according to the maturation stage and the treatment. 400 
Similarly, an increase in EI was observed when the aarGths were combined or when aarLh 401 
alone was administered, nevertheless aarFsh alone registered a lower EI. Results from 402 
previous studies corroborate our data, since consecutive injections with eel Lh-producing 403 
implants induced a significant increase in the EI in European eel females (Ron Dirks, 404 
personal communication). Furthermore, the coexistence of duplicated Lh receptors in the 405 
European eel genome has recently been demonstrated [36]. A comparative tissue 406 
distribution study in silvering migrating females, a high expression of both Lh receptors 407 
but no Fsh receptor expression was reported in eye tissue. This therefore would indicate 408 
that aarLh is the main factor involved in inducing eye development and EI increase. 409 
The FC became darker throughout the course of maturation, irrespective of the treatment. 410 
This could mean that both rGths stimulate this process. Rohr et al. [37] proposed that 11-411 
KT was responsible for silvering in short-finned eel (Anguilla australis). This hipothesis 412 
is supported by our results, since darker fins and higher 11-KT plasma levels were 413 
registered in the same weeks. 414 
All hormonal treatments were able to promote spermatogenesis, but only group F/LI 415 
induced a significant increase in the GSI (around 4%). This value was lower than the 416 
values previously registered using rhCG hormones with maximum values of 10%, 417 
hormonal treatment which have been demonstrated until now the most effective to mature 418 
male eel in captivity [3,38], what indicates that the treatments used in the first experiment 419 
can be improved. 420 
The lowest GSI values were obtained in the groups L and F/L, what may indicate that the 421 
stimulation of the Fsh receptor is crucial in order to complete spermatogenesis, since a 422 
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total or temporary lack of Fsh has a negative impact on gonad development. On the other 423 
hand, in Japanese eel, the administration of only ajrLh (produced in baculovirus-silkworm 424 
larvae system) was able to induce a higher GSI than ajrFsh alone [20,22]. The differences 425 
in these studies could be explained by the fact that different systems have been used to 426 
produce the rGths, meaning that their bioactivity and half-life could differ [39]. In fact, 427 
the level of testis development in Japanese eel reached using ajrGths was lower than that 428 
obtained in this study with either aarGths (Fig. 3) or hCG [15,40], both of which resulted 429 
in complete testis maturation. Therefore, further in vivo studies on the interaction between 430 
Gths and their receptors are necessary. 431 
Progression of gonad development 432 
All the treatments, with the exception of group L (treated with only aarLh), induced 433 
complete spermatogenesis, with the most advanced stages of gonad development (SPZ1 434 
and 2) being reached. aarFsh was able not only to induce complete spermatogenesis, as 435 
previously observed in vitro in Japanese eel [19,41], but even 50% of spermiating males. 436 
Fish from treatment F/L, in which aarFsh administration was arrested after 4 weeks, 437 
showed abnormal testis development, with a few spermatozoa cysts in small gonads (GSI 438 
0.15-0.16%) showing type A spermatogonia, but no spermatocytes nor spermatids, which 439 
is the common feature when spermatozoa are present. Two processes could explain this: 440 
either the spermatocytes, spermatids, or most type B spermatogonia, have undergone an 441 
apoptotic process and were not present in the testes, leaving some spermatozoa cysts, or 442 
an abnormal restricted meiosis and spermiogenesis have happened only in a few cysts. 443 
We consider the first hypothesis, a regression after Fsh cessation, to be more likely, as 444 
apoptotic cells were found.  445 
aarLh stimulated the onset of testis maturation, but it did not induce complete 446 
spermatogenesis by itself, unlike Japanese eel rLhs [20]. In fact, in Japanese eel, ajrLh 447 
(produced by silkworm larvae) resulted in a higher level of testis development than ajrFsh 448 
[22]. Other studies on Japanese eel have shown that ajrFsh (produced in a Drosophila 449 
expression system) was able to stimulate the recombinant Fsh receptor even at low doses, 450 
but not the Lh receptor. Furthermore ajrLh activated both Gths receptors, although only 451 
at high doses [19]. Similar results have been observed in other teleosts [42–44]. 452 
Therefore, one possible explanation for the differences found between the Japanese and 453 
European eel results could be the fact that the minimum aarLh dose required to stimulate 454 
both receptors and obtain a complete spermatogenesis is higher than the one we used in 455 
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the current study. Moreover, other factors, such as the number of receptors or their 456 
sensitivity could also have an effect, and therefore new studies are required in order to 457 
understand the mechanism. 458 
Steroid evolution during hormonal treatment 459 
In previous studies, all Japanese eel rGths were able to induce testis steroidogenesis 460 
[14,17,19,22], increasing the T and 11-KT levels both in vitro and in vivo. Furthermore, 461 
it is known that in Japanese eel 11-KT alone is able to induce complete spermatogenesis 462 
in vitro [41]. In the present study, when both aarGths were administered separately they 463 
were able to induce androgen steroidogenesis, and resulted in similar profiles. Thus, a 464 
lack of 11-KT in aarLh-treated fish (group F, Fig. 6A) would not explain the differences 465 
in maturation between aarLh and aarFsh treated fish.  466 
Similar androgen production levels were observed using a sequential treatment; first 467 
aarFsh and later aarLh (group F/L). But,  the abnormal testis development found in the 468 
F/L group would suggest that, unlike what happens in Japanese eel testis in vitro [41], the 469 
androgen synthesis was not enough to achieve complete spermatogenesis in vivo. This is 470 
corroborated by studies on zebrafish which have shown that Fsh has a direct effect on the 471 
testis, not mediated by androgen production. Zebrafish testes cultured with rFsh and 472 
trilostane (a 3β-hydroxisteroid dehydrogenase inhibitor blocking the steroid production), 473 
showed an up-regulation of gene expression in Leydig cells: insl3, cyp17a1 [24] and Igf3 474 
[45]. This in turn stimulated the proliferation and differentiation of the spermatogonia, as 475 
well as the beginning of meiosis and development into adult zebrafish testis [45]. 476 
On the other hand, 11-KT production was higher in the fish treated with both aarGths 477 
(groups F/LI and FD/LI). These groups reached the last stages of maturation and induced 478 
sperm production earlier than the other groups. 479 
Sperm quality parameters 480 
In previous studies, complete in vivo spermatogenesis of immature Japanese eel males 481 
has been accomplished after treatment with rGths, but unlike the current study no 482 
spermiating male has been obtained [20–22]. Treatment with rGths has resulted in 483 
spermiating males in Japanese eel and other teleosts [27,28], but the treated fish were 484 
already sexually mature. Therefore, as far as we know, this is the first study where 485 
spermiating males have been obtained after rGths treatment using totally immature male 486 
fish.  487 
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The sperm quality was different depending on the hormonal treatment. Although the 488 
histological features from the testis in SPZ1 or SPZ2 from treatments F, F/LI and FD/LI 489 
were similar, the best sperm quality was observed in group F/LI, with almost 100% 490 
spermiating males and 20% sperm motility. This group also showed higher levels of testis 491 
growth (GSI), sperm volume and sperm density, indicating that a sustained level of aarFsh 492 
and an increasing level of aarLh is a good system for inducing the highest sperm 493 
production and quality. Even so, the sperm quality was significantly lower than that 494 
registered when using rGths of human origin (rhCG; [3,46]). Consequently, taking into 495 
account the results observed in Experiment 1, new hormonal treatments were assayed in 496 
Experiment 2. 497 
Experiment 2 498 
In this second experiment, we confirmed that the combination of both rGths is necessary 499 
to induce the sex maturation of European eel in captivity. The High treatment group 500 
showed similar results in terms of gonad development to the High group in experiment 1. 501 
2.8 µg aarFsh/fish was established as the minimum effective dose to induce maturation 502 
in male European eel. Moreover, doses higher than 2 µg aarLh/fish registered better 503 
results in terms of sperm quality. 504 
Biometric parameters: EI, FC and GSI 505 
Generally, EI levels were higher in this second experiment than in the first. The aarLh 506 
doses were higher in this second experiment, supporting the hypothesis that aarLh is main 507 
factor contributing to the increase in EI. In terms of FC change, the results were similar 508 
to those of the first experiment, with high 11-KT levels coinciding with darker fins.  509 
Unlike in Experiment 1, all the treatments in Experiment 2 resulted in a significant 510 
increase in the GSI, confirming that combining both rGths is the best method of inducing 511 
eel maturation. No significant differences were observed in the GSI of group F/LI from 512 
Experiment 1 (3.83%; 4 µg aarFsh/fish) and that of the High treatment group from 513 
Experiment 2 (4.3%; 2.8 µg aarFsh/fish). This suggests that 2.8 µg aarFsh/fish is the 514 
minimum effective dose for inducing gonad development.  515 
Progression of gonad development 516 
All three treatments (High, Medium and Low) induced complete spermatogenesis, but 517 
the progression of gonad development was delayed and the percentage of fish observed 518 
in the spermiating stages (SPZ1 and 2) was lower in the Medium and Low groups. These 519 
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results suggest that the administration of rFsh is relevant for the advancement of 520 
spermatogenesis. On the other hand, in previous experiences, rhCG treatments reported 521 
faster progression in spermatogenesis and a higher percentage of spermiating males 522 
[3,7,38]. Thus, further studies are necessary to test if any alternative treatments are able 523 
to yield the same or better results than those observed using the traditional method with 524 
rhCG. 525 
Steroid evolution during hormonal treatment 526 
The androgen profiles in this second experiment were similar to those obtained in 527 
experiment 1, with higher levels (only significant in the High group) being reached at 528 
around week 6 and levels later decreasing (around week 9). However, although the 529 
androgen profiles were similar, the results in terms of gonad development were different, 530 
with the fish in the second experiment maturing further (reaching the SPD stage at least). 531 
These results support the theory that androgen levels on their own are not enough to 532 
induce complete spermatogenesis in vivo, and that rGths may have a direct effect on the 533 
testes. In fact, 11-KT implants in male short-finned eel (Anguilla australis) were not able 534 
to induce the same stage of maturation as hCG treatment [47]. 535 
Sperm quality parameters 536 
Motilities close to 60% were registered in the High treatment group. These values are 3 537 
times higher than the best values obtained in experiment 1, and similar to those reported 538 
with the use of rhCG [3,46,48]. With regards to other sperm parameters, such as density, 539 
progressive motility and kinetic parameters (VCL and VSL), the values observed were 540 
similar to those reported in experiments using rhCG [3]. Nevertheless, the volume was 541 
lower than that achieved by hCG treatments [7]. Moreover, after a progressive increase 542 
in sperm quality up to week 10, a subsequent decrease was observed, while longer 543 
spermiation periods were found with rhCG treatments [3].  544 
In this second experiment, the combination of both aarGths and higher levels of aarLh 545 
resulted in an improvement in sperm quality compared to experiment 1, but without 546 
reaching the values reported with rhCG treatments. In consequence, further studies are 547 
necessary in order to find out the proper aarGth amount and/or timing of administration. 548 
In conclusion, this study has demonstrated that aarGths are able to induce the spermiation 549 
in European eel, and confirmed that the half-life of these rGths is long enough to induce 550 
in vivo effects. Nevertheless, due to the fact that a decrease in sperm quality was observed 551 
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at the end of the treatment, further experiments combining these recombinant hormones 552 
are required in order to improve hormonal treatments.  553 
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Figure legends 714 
 715 
Figure 1. Descriptive diagram of the hormonal treatments for the five experimental 716 
groups in the experiment 1. 717 
 718 
Figure 2. Descriptive diagram of hormonal treatments for the three experimental groups 719 
in the experiment 2. 720 
 721 
Figure 3. Gonadosomatic indexes before hormone administration (freshwater (FW) and 722 
seawater (SW) conditions) and at the end of hormonal treatments (groups F and L until 723 
9th week; groups F/L, F/LI and FD/LI until 11th week) in the experiment 1. Data are 724 
expressed as mean ± SEM (n = 6-8 per sampling and treatment). Asterisk indicates 725 
significant differences between treatments at the end of the trial. 726 
 727 
Figure 4. Relative percentages of the stages of testis development (SPG1-SPZ2) at the 728 
end of the hormonal treatments in the experiment 1 (groups F and L until 9th week; groups 729 
F/L, F/LI and FD/LI until 11th week; n= 6-8). See main text for definition of gonad 730 
developmental stages: Stages: SPG1: Spermatogonia 1; SPG2: Spermatogonia 2; SPC1: 731 
Spermatocyte 1; SPC2: Spermatocyte 2; SD: Spermatid; SPZ1: Spermatozoa 1; SPZ2: 732 
Spermatozoa 2; Regression. 733 
 734 
Figure 5. Histological sections of testis from different treatments (experiment 1). A) 735 
aarFsh alone, 9 weeks; stage SPZ1; B) aarLh alone, 9 weeks, SPG2 stage; C) 736 
aarFsh+aarLh, 12 weeks, SPZ2 stage; D) aarFsh+aarLh 3, 12 weeks, regression. Scale 737 
bar: A=100 µm; B, C, D= 10 µm. See main text for definition of gonad developmental 738 
stages: SPGA (spermatogonia A); SPGAdiff (spermatogonia A differenciated); SPGB 739 
(spermatogonia B); SPC I (spermatocyte I); SPD (spermatid), SPZ (spermatozoa); Ap 740 
(apoptotic cells).  741 
 742 
Figure 6. Profile plasma levels of testosterone (T) and 11-ketotestosterone (11-KT) 743 
before hormone administration (sea water conditions, SW) and throughout the hormonal 744 
treatments (groups F and L until 9th week; groups F/L, F/LI and FD/LI until 11th week) in 745 
the experiment 1. Steroid levels (T and 11-KT) are represented as fold change with respect 746 
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to the mean value of samples from freshwater fish (1.80 ± 0.14 ng T/ml and 0.29 ± 0.05 747 
ng 11-KT/ml). Data are expressed as mean ± SEM (n = 6-8 per sampling and treatment). 748 
Different letters indicate significant differences over the weeks within the same hormonal 749 
treatment. 750 
 751 
Figure 7. Evolution of sperm production parameters throughout the recombinant 752 
gonadotropin treatments (groups F and L until 9th week; groups F/L, F/LI and FD/LI until 753 
11th week) in the experiment 1. A) Percentage of spermiating males; B) Sperm volume; 754 
and C) Sperm density.  Data are expressed as mean ± SEM (n = 6-8 per sampling and 755 
treatment). Capital letters indicate statistical differences between groups (treatments), and 756 
lowercase letters indicate statistical differences over the time in the same treatment. 757 
 758 
Figure 8. Evolution of sperm kinetic parameters throughout the recombinant 759 
gonadotropin treatments (groups F and L until 9th week; groups F/L, F/LI and FD/LI until 760 
11th week) in the experiment 1. A) Total motility; B) Progressive motility; C) Curvilinear 761 
velocity (VCL); and D) Rectilinear velocity (VSL). Data are expressed as mean ± SEM 762 
(n = 6-8 per sampling and treatment). Capital letters indicate statistical differences 763 
between groups (treatments), and lowercase letters indicate statistical differences over the 764 
time in the same treatment. 765 
 766 
Figure 9. Gonadosomatic indexes of three experimental groups (High, Medium and Low 767 
treatments) over the weeks in the experiment 2. Data are expressed as mean ± SEM (n = 768 
3-7). Asterisk indicates significant differences between groups at the same week and 769 
different letters indicate significant differences between weeks for the same hormonal 770 
treatment. 771 
 772 
Figure 10. Profile plasma levels of testosterone (T) and 11-ketotestosterone (11-KT) 773 
before hormone administration (sea water conditions, SW) and throughout the hormonal 774 
treatments (High, Medium and Low) in the experiment 2. Steroid levels (T and 11-KT) 775 
are represented as fold change with respect to the mean value of samples from freshwater 776 
fish (2.12 ± 0.22 ng T/ml and 1.80 ± 0.21 ng 11-KT/ml). Data are expressed as mean ± 777 
SEM (n = 3-7 per sampling and treatment). Different letters indicate significant 778 




Figure 11. Evolution of sperm production parameters throughout the recombinant 781 
gonadotropin treatments (High, Medium and Low) in the experiment 2. A) Percentage of 782 
spermiating males; B) Sperm volume; and C) Sperm density. Data are expressed as mean 783 
± SEM (n = 3-7 per sampling and treatment). Capital letters indicate statistical differences 784 
between groups (treatments), and lowercase letters indicate statistical differences over the 785 
time in the same treatment. 786 
 787 
Figure 12. Evolution of sperm kinetic parameters throughout the recombinant 788 
gonadotropin treatments (High, Medium and Low) in the experiment 2. A) Total motility; 789 
B) Progressive motility; C) Curvilinear velocity (VCL); and D) Rectilinear velocity 790 
(VSL). Data are expressed as mean ± SEM (n = 3-7 per sampling and treatment). Capital 791 
letters indicate statistical differences between groups (treatments), and lowercase letters 792 







Supplementary Figure 1 Histological sections of eel testis at different developmental 800 
stages. A) Testis at SPG1. B) Testis at SPG2. C) Testis at SPC1. D) Testis at SPC2. E) 801 
Testis at SPD. F) Testis at SZ1. G, H) Testis at SZ2. See main text for definition of gonad 802 
developmental stages. SPGA= Spermatogonia type A; SPGB= Spermatogonia type B; 803 
SPC: Spermatocytes; SPD: Spermatids; SPZ: Spermatozoa. Scale bars, 25 μm (A, B, C, 804 
D, E, F, H) and 100 μm (G). 805 
   806 
26 
 
Table legends 807 
 808 
Table 1. Biometric parameters (eye index and fin colour) before hormone administration 809 
(freshwater, FW; and sea water, SW) and over the weeks of hormonal treatments on the 810 
five experimental groups in the experiment 1 (groups F and L until 9th week; groups F/L, 811 
F/LI and FD/LI until 11th week) 6-8. Data are expressed as mean (SEM); n= 6-8. Different 812 
letters indicates significant differences between groups at the same week and different 813 
letters indicate significant differences among weeks for the same hormonal treatment. 814 
 815 
Table 2. Biometric parameters (eye index and fin colour) over the weeks in the three 816 
experimental groups (High, Medium and Low) in the experiment 2. Data are expressed 817 
as mean (SEM); n= 3-7. Different letters indicates significant differences between groups 818 
at the same week and different letters indicate significant differences among weeks for 819 
the same hormonal treatment. 820 
 821 
Table 3. Distribution of stages of testis development reached by the different males 822 
through the samplings (W3-12) in the three experimental groups: (●) High (2.8 µg 823 
aarFsh/fish); (●) Medium (1.4 µg aarFsh/fish); and (○) Low (0.7 µg aarFsh/fish). Stages: 824 
SPG1: Spermatogonia 1; SPG2: Spermatogonia 2; SPC1: Spermatocyte 1; SPC2: 825 
Spermatocyte 2; SD: Spermatid; SPZ1: Spermatozoa 1; SPZ2: Spermatozoa 2.  826 
27 
 
















































Figure 2  829 
 830 
Weeks of Treatment






























Figure 3 832 
Weeks of Treatment
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Figure 4 835 
 836 
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Figure 6 845 
 846 
Weeks of Treatment
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Figure 9  856 
 857 
Weeks of Treatment



















  859 
36 
 
Figure 10 860 
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Table 1 870 
  871 
 Eye Index              Fin Colour        
 
  
 Group F  Group L  Group F/L  Group F/LI  Group FD/LI  Group F  Group L  Group F/L  Group F/LI  Group FD/LI 
FW 3.8 (0.1) c  3.8 (0.1) c  3.8 (0.1) c  3.8 (0.1) d  3.8 (0.1) c  1.8 (0.3)  1.8 (0.3)  1.8 (0.3)  1.8 (0.3)  1.8 (0.3) 
SW 4.7 (0.1) ab  4.7 (0.1) b  4.7 (0.1) ab  4.7 (0.1) bc  4.7 (0.1) ab  2.7 (0.4)  2.7 (0.4)  2.7 (0.4)  2.7 (0.4)  2.7 (0.4) 
W3 4.4 (0.2) abc  4.8 (0.2) b  4.4 (0.2) bc  5.3 (0.3) ab  3.9 (0.1) c  3.3 (0.3)  3.3 (0.2)  2.1 (0.1)  3.4 (0.4)  3.1 (0.3) 
W5 4.1 (0.1) bc  4.5 (0.1) b  4.3 (0.2) bc  4.5 (0.2) c  4.5 (0.2) b  4.0 (0.0)  3.9 (0.1)  3.0 (0.3)  3.8 (0.3)  3.9 (0.1) 
W7 4.2 (0.2) bc  5.1 (0.2) ab  4.8 (0.2) ab  4.8 (0.1) bc  4.4 (0.2) b  4.0 (0.0)  3.8 (0.2)  4.0 (0.0)  4.0 (0.0)  4.0 (0.0) 
W9 4.9 (0.2) a  5.6 (0.3) a  5.2 (0.1) a  5.3 (0.2) ab  4.8 (0.1) ab  4.0 (0.0)  3.8 (0.2)  4.0 (0.0)  4.0 (0.0)  4.0 (0.0) 
W11       5.3 (0.3) a  5.7 (0.2) a  5.1 (0.2) a        3.6 (0.2)  4.0 (0.0)  4.0 (0.0) 
                              
40 
 
Table 2 872 
 873 
  874 
 Eye Index        Fin Colour       
 High  Medium  Low  High  Medium  Low 
SW 3.3 (0.2) c  3.3 (0.2) c  3.3 (0.2) c  1.0 (0.0)  1.0 (0.0)  1.0 (0.0) 
W3 4.6 (0.1) b  4.2 (0.2) b  4.0 (0.2) bc  2.7 (0.3)  1.3 (0.3)  2.0 (0.0) 
W6 5.0 (0.2) b  4.4 (0.2) b  3.8 (0.4) bc  4.0 (0.0)  2.7 (0.3)  3.0 (0.6) 
W9 5.4 (0.5) a  6.5 (0.7) ab  4.7 (0.4) ab  4.0 (0.0)  4.0 (0.0)  3.3 (0.3) 
W12 7.0 (0.6) a  5.8 (0.3) a  5.6 (0.2) a  3.7 (0.3)  3.1 (0.3)  3.7 (0.2) 
                  
41 
 
Table 3 875 
 876 

















   




























Appendix A 878 
 879 
 880 
Figure 1 Histological sections of eel testis at different developmental stages. A) Testis at 881 
SPG1. B) Testis at SPG2. C) Testis at SPC1. D) Testis at SPC2. E) Testis at SPD. F) 882 
Testis at SZ1. G, H) Testis at SZ2. See main text for definition of gonad developmental 883 
stages. SPGA= Spermatogonia type A; SPGB= Spermatogonia type B; SPC: 884 
Spermatocytes; SPD: Spermatids; SPZ: Spermatozoa. Scale bars, 25 μm (A, B, C, D, E, 885 
F, H) and 100 μm (G). 886 
  887 
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Figure 2. Evolution total motility throughout the recombinant gonadotropin treatments 890 
in the experiment 1: Group F ( ), Group F/L ( ), Group F/LI ( ), and Group FD/LI ( ) 891 
treatment. Each point means a data from an individual male.  892 
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Figure 3. Evolution total motility throughout the recombinant gonadotropin treatments 894 
in the experiment 2: High ( ), Medium ( ), and Low ( ) treatment. Each point 895 
means a data from an individual male. 896 
